The EGFR/HER2 inhibitor varlitinib is used for the treatment of triple-negative breast cancer (TNBC), and its impact on LPS-induced neuroinflammation and the underlying mechanism of action have received little attention. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.